GOSSAMER BIO INC

Insider buying fuels optimism for Gossamer Bio’s PAH drug pipeline; board member Milligan’s option exercise signals strong confidence in seralutinib’s regulatory and commercial upside.

Insider buys 10,000 Gossamer Bio shares after NDA filing for seralutinib, signaling confidence in a future FDA win and potential upside for investors.